Literature DB >> 35450363

Novel Plasma Kallikrein Inhibitors for Treating Hereditary Angioedema, Diabetic Macular Edema, and Diabetic Retinopathy.

Ram W Sabnis1.   

Abstract

Entities:  

Year:  2022        PMID： 35450363      PMCID： PMC9014518          DOI： 10.1021/acsmedchemlett.2c00085

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.632


× No keyword cloud information.
  6 in total

Review 1.  Extracellular vesicles in renal inflammatory and infectious diseases.

Authors:  Diana Karpman; Ashmita Tontanahal
Journal:  Free Radic Biol Med       Date:  2021-04-29       Impact factor: 7.376

Review 2.  Discovery and development of plasma kallikrein inhibitors for multiple diseases.

Authors:  Zhouling Xie; Zhen Li; Yanruisheng Shao; Chenzhong Liao
Journal:  Eur J Med Chem       Date:  2020-02-10       Impact factor: 6.514

Review 3.  Hemodialysis-Related Complement and Contact Pathway Activation and Cardiovascular Risk: A Narrative Review.

Authors:  Sarah C Skinner; Vimal K Derebail; Caroline J Poulton; Donna C Bunch; Prabir Roy-Chaudhury; Nigel S Key
Journal:  Kidney Med       Date:  2021-06-09

Review 4.  Clinical manifestations of hereditary angioedema and a systematic review of treatment options.

Authors:  Mattie Rosi-Schumacher; Sejal J Shah; Timothy Craig; Neerav Goyal
Journal:  Laryngoscope Investig Otolaryngol       Date:  2021-04-03

Review 5.  Novel anti-thrombotic mechanisms mediated by Mas receptor as result of balanced activities between the kallikrein/kinin and the renin-angiotensin systems.

Authors:  Chao Fang; Alvin H Schmaier
Journal:  Pharmacol Res       Date:  2020-07-24       Impact factor: 7.658

Review 6.  Proteolytic activity of contact factor zymogens.

Authors:  Aleksandr Shamanaev; Jonas Emsley; David Gailani
Journal:  J Thromb Haemost       Date:  2020-12-07       Impact factor: 5.824
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.